{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:46:58Z","timestamp":1790779618931,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["5T15LM007124-24"],"award-info":[{"award-number":["5T15LM007124-24"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010573","name":"Center for Clinical and Translational Science, University of Utah","doi-asserted-by":"publisher","award":["UM1TR004409"],"award-info":[{"award-number":["UM1TR004409"]}],"id":[{"id":"10.13039\/100010573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010573","name":"Center for Clinical and Translational Science, University of Utah","doi-asserted-by":"publisher","award":["UM1TR004409"],"award-info":[{"award-number":["UM1TR004409"]}],"id":[{"id":"10.13039\/100010573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03310-7","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:06:31Z","timestamp":1778511991000},"page":"1519-1527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the indirect interaction between glucagon-like peptide-1 receptor agonists and warfarin using real-world data"],"prefix":"10.1007","volume":"59","author":[{"given":"Spencer J.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara R.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkiran","family":"Gouripeddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Facelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"4","key":"3310_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740\u2013756","journal-title":"Cell Metab"},{"key":"3310_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","volume":"128","author":"NK Smith","year":"2019","unstructured":"Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94\u2013105","journal-title":"Neurochem Int"},{"issue":"10278","key":"3310_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al (2021) Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984","journal-title":"Lancet"},{"issue":"10402","key":"3310_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402(10402):613\u2013626","journal-title":"Lancet"},{"issue":"3","key":"3310_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"issue":"1","key":"3310_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11\u201322","journal-title":"N Engl J Med"},{"issue":"11","key":"3310_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"key":"3310_CR8","unstructured":"Novo Nordisk (2024) Wegovy (semaglutide) [package insert]. US Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf. Revised July 2023. Accessed October"},{"key":"3310_CR9","unstructured":"Novo Nordisk (2014) Saxenda (liraglutide) [package insert]. US Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321Orig1s000lbl.pdf. Revised December Accessed October 2024"},{"key":"3310_CR10","unstructured":"Eli Lilly and Company (2024) Zepbound (tirzepatide) [package insert]. US Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf. Revised November 2023. Accessed October"},{"issue":"8","key":"3310_CR11","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","volume":"31","author":"M Ukhanova","year":"2025","unstructured":"Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause TM (2025) Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am J Manag Care 31(8):e228\u2013e34","journal-title":"Am J Manag Care"},{"issue":"2 Suppl","key":"3310_CR12","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e44S\u2013e88S","journal-title":"Chest"},{"issue":"1","key":"3310_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","volume":"41","author":"DM Witt","year":"2016","unstructured":"Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE (2016) Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis 41(1):187\u2013205","journal-title":"J Thromb Thrombolysis"},{"key":"3310_CR14","unstructured":"Shikdar S, Vashisht R, Zubair M, Bhattacharya PT International Normalized Ratio: Assessment, Monitoring, and Clinical Implications. StatPearls. Treasure Island (FL)2025"},{"issue":"9","key":"3310_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","volume":"58","author":"TA Baekdal","year":"2019","unstructured":"Baekdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW (2019) Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet 58(9):1193\u20131203","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3310_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40262-019-00757-1","volume":"58","author":"K Bogman","year":"2019","unstructured":"Bogman K, Brumm J, Hofmann C, Giraudon M, Niggli M, Sturm-Pellanda C et al (2019) Assessment of drug-drug interactions between taspoglutide, a glucagon-like peptide-1 agonist, and drugs commonly used in type 2 diabetes mellitus: results of five phase I trials. Clin Pharmacokinet 58(9):1205\u20131214","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3310_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","volume":"47","author":"B Calvarysky","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD (2024) Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf 47(5):439\u2013451","journal-title":"Drug Saf"},{"issue":"11","key":"3310_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40262-017-0532-6","volume":"56","author":"H Hausner","year":"2017","unstructured":"Hausner H, Derving Karsbol J, Holst AG, Jacobsen JB, Wagner FD, Golor G et al (2017) Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet 56(11):1391\u20131401","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"3310_CR19","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","volume":"132","author":"SR Vazquez","year":"2018","unstructured":"Vazquez SR (2018) Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood 132(21):2230\u20132239","journal-title":"Blood"},{"key":"3310_CR20","unstructured":"TriNetX L TriNetX Research Collaborative Network 2024. Available from: https:\/\/trinetx.com"},{"issue":"3","key":"3310_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236\u2013239","journal-title":"Thromb Haemost"},{"issue":"403","key":"3310_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/01621459.1988.10478639","volume":"83","author":"WS Cleveland","year":"1988","unstructured":"Cleveland WS, Devlin SJ (1988) Locally weighted regression - an approach to regression-analysis by local fitting. J Am Stat Assoc 83(403):596\u2013610","journal-title":"J Am Stat Assoc"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03310-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:17:01Z","timestamp":1786007821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03310-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03310-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}